Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 381Breast Neoplasms 364Colorectal Neoplasms 238Stomach Neoplasms 218Carcinoma, Hepatocellular 155Lung Neoplasms 123Neoplasms 120Pancreatic Neoplasms 109Prostatic Neoplasms 100Neoplasm Metastasis 96Recurrence 95Rectal Neoplasms 95Ovarian Neoplasms 90Nasopharyngeal Carcinoma 88Esophageal Neoplasms 82Esophageal Squamous Cell Carcinoma 81Lymphoma, Large B-Cell, Diffuse 79Melanoma 75Small Cell Lung Carcinoma 71Uterine Cervical Neoplasms 70Lymphoma 70Leukemia, Myeloid, Acute 70Brain Neoplasms 69Sarcoma 68Head and Neck Neoplasms 68Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 65Carcinoma, Renal Cell 63Triple Negative Breast Neoplasms 61Lymphoma, Non-Hodgkin 53

Interventions

Cetuximab 1CCT239065 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unknown × CRC × Clear all
NCT04984369 2023-08-21

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Shanghai Henlius Biotech

Phase 2 Unknown
50 enrolled

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡